Skip to main content
. 2023 Nov 21;31(1):10–17. doi: 10.1097/GME.0000000000002278

TABLE 2.

Characteristics of KEEPS continuation participants at KEEPS baseline by randomization group

All (n = 299) oCEE (n = 90) tE2 (n = 96) Placebo (n = 113) Overall P value
Age (y) 54 (2) 54 (3) 54 (2) 54 (2) 0.77
BMI (kg/m2) 25.9 (4.3) 26.1 (4.4) 25.4 (4.2) 26.2 (4.3) 0.39
Waist/hip ratio 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.84
Diabetes, n (%) 0 0 0 0
Smoker, n (%) 12 (4) 1 (1) 5 (5) 6 (5) 0.22
Systolic BP (mm Hg) 117 (14) 118 (14) 116 (15) 118 (15) 0.53
Diastolic BP (mm Hg) 74 (9) 75 (8) 73 (9) 75 (9) 0.17
Total cholesterol (mg/dL) 209 (33) 213 (32) 207 (33) 208 (36) 0.43
HDL-C (mg/dL) 73 (14) 74 (14) 75 (15) 72 (14) 0.39
LDL-C (mg/dL) 113 (29) 117 (30) 110 (29) 112 (27) 0.24
Triglycerides (mg/dL) 85 (55) 83 (61) 81 (44) 88 (59) 0.64
Glucose (mg/dL) 80 (9) 80 (10) 79 (8) 80 (10) 0.96
Insulin (mcU/mL) 6.1 (9.4) 4.8 (3.9) 6.7 (13.8) 6.7 (7.8) 0.28
HOMA-IR 1.3 (2.1) 1.0 (0.8) 1.4 (3.1) 1.4 (1.7) 0.46a
Heart attack or angina, n (%) 0 0 0 0
Congestive heart failure, n (%) 0 0 0 0
Stroke, n (%) 0 0 0 0

Characteristics represent data collected between years 2005 and 2008 before the time when women were recontacted for the KEEPS continuation study. Data shown are mean (SD) or n (%). Groupwise P values comparing treatment to placebo are from Fisher exact test or analysis of variance followed by Tukey pairwise tests, as appropriate.

BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; KEEPS, Kronos Early Estrogen Prevention Study; LDL-C, low-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance.

aP value is from log-transformed HOMA-IR.